VBL Therapeutics presents two studies on VB-111 of the AACR 102nd Annual meeting

Current article ratings:
Patients / public:healthcare Prof:
VBL Therapeutics, a clinical stage biotechnology company committed to the development of novel therapies for immune inflammatory diseases and cancer, preclinical announced data demonstrated VB-111 potential utility as a targeted cancer therapy. The company presents two studies, proof of safety and feature of VB-111 and the other demonstrates its promise against glioblastoma, at the American Association for cancer research (AACR) 102nd Annual meeting, held this week in Orlando, Florida

VB-111 is the first targeted, dual-action, anti-angiogenesis and vascular disruptive agent (VDA) VTS ™, the company's, proprietary platform technology for the treatment of cancer shows. VB-111 VDA, similar to working a "biological knife" in a way, is an IV managed tumor vascular system, so cut from the blood vessels feeding the tumor to destroy.

"We are pleased about the opportunity to present this data at AACR by our esteemed ladies and gentlemen," said Yael Cohen, MD, Vice President of clinical development at VBL. "These data show VB-111 promise as a targeted cancer treatment currently studied in phase 2 clinical trials in thyroid cancer and glioblastoma." "VB 111 unique mechanism of action is tumors with precision and specificity, which caused no significant damage the normal non-cancerous tissue or the normal Vasculatures in the body."

The first study showed that VB-111 was provide safe and special additive effect of chemotherapy. Researchers the safety and efficacy of VB-111 as monotherapy, in combination with bevacizumab in combination with carboplatin and Pemetrexed in a Lewis lung metastasis model evaluated and found that VB-111 a dose dependent tumor induced reduction of up to 90 percent.

The second study found that VB-111 promise for the treatment of glioblastoma has. Researchers assessed the effects of VB-111 on tumor growth in rats with established intracranial Xenografts. The results show reduced tumor size in animals with VB-111, with these rats a median survival of 48 days shows handles 38 days for untreated rats, opposite. VBL evaluated currently VB-111 in a phase 1 / 2 study in patients with glioblastoma.

About VB-111

VB-111 is a dual-action and anti-angiogenesis vascular disruptive agent (VDA), the VTS ™, use VBL's proprietary platform technology for treatment of cancer. VB-111 is an intravenously administered VDA, similar to working a "biological knife" in a way, tumor vascular system, so cut from the blood vessels feeding the tumor to destroy.

Non-clinical studies of VB-111 pharmacological and Toxicology tissue showed specificity for the tumour tissue, no material injury normal non-cancerous tissue or the normal Vasculatures in the body and a more than 90 percent decline in the metastatic lung cancer model with an injection, as well as similar effectiveness in other tumor models. A phase 1 "all comers" study of VB-111 in 33 patients with advanced metastatic cancer shown antitumor activity and no effect on the liver function or major changes in blood cell count. VB-111 is currently in phase 2 trials for thyroid cancer and glioblastoma.

Source:
VBL Therapeutics